WMSA
VIRX

Weiss Multi-Strategy Advisers’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Weiss Multi-Strategy Advisers’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-190
Closed -$102K – 534
2014
Q4 		$102K Buy
+190
New +$85.6K ﹤0.01% 393

Other funds holding VIRX

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
First Eagle Investment Management
First Eagle Investment Management New York $59.9B AUM 27.01% 1-Year Est. Return
FWM
Frontier Wealth Management Kansas City, Missouri $1.38B AUM 6.3% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

Weiss Multi-Strategy Advisers's VIRX Position: Q3 2016 in Review

Weiss Multi-Strategy Advisers sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2016, closing a stake of 104 shares — an estimated $12K sold.

Weiss Multi-Strategy Advisers first reported a position in VIRX in Q4 2014 and held it in 7 quarters. The position peaked at $169K in Q2 2015. 40 funds tracked by Wall St. Rank hold VIRX as of Q3 2016.

  • Weiss Multi-Strategy Advisers reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2016 after selling out during the quarter.
  • Weiss Multi-Strategy Advisers sold 104 Viracta Therapeutics, Inc. Common Stock shares in Q3 2016, an estimated $12K.
  • Weiss Multi-Strategy Advisers first reported a position in Viracta Therapeutics, Inc. Common Stock in Q4 2014 and held it in 7 quarters.
  • Weiss Multi-Strategy Advisers's Viracta Therapeutics, Inc. Common Stock position peaked at $169K in Q2 2015.
  • 40 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2016.

Based on Weiss Multi-Strategy Advisers's 13F filing for Q3 2016, filed 14 Nov 2016.